🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
H. Lundbeck A/S (CPH:HLUN.B)
Denmark flag Denmark · Delayed Price · Currency is DKK
62.05
+0.25 (0.40%)
Nov 20, 2026, 11:21 AM CET
← View all transcripts

Jefferies Global Healthcare Conference

Nov 17, 2026

Summary

Vyepti and Rexulti underpin durable growth, while late-stage pipeline catalysts include bexicaserin results by end-2026 and Q1 2027, plus amlenetug in Q3 2027. The scale phase prioritizes reinvestment, pipeline expansion, and long-term growth.

Shan Hama
Analyst, Jefferies

Hi, everyone. Welcome to the Jefferies London Healthcare Conference. I'm Shan Hama from the European Pharma and Biotech team here at Jefferies. I'm grateful to be joined by the CEO of Lundbeck, Charl van Zyl, who will start with a presentation before we go into Q&A. Please go ahead.

Charl van Zyl
CEO, Lundbeck

Thank you, Shan. Thanks for the opportunity to present an update on Lundbeck, and of course, welcome everybody here in the room as well. Some of you have followed us, of course, over the years, but about three years ago, we established a multi-year strategic reset for Lundbeck, and we are three years into that journey. The focus of that first three years was to ensure that we grow more with what we have. Secondly, to build a very compelling long-term pipeline. The third was to ensure that we are disciplined and strategic in our capital allocation to fund either growth or innovation. Of course, as we stand here today, I'm very confident that we have made that transition, that transformation, to set up the company for the next chapter in its strategic path.

Today, my presentation will be there to really provide you with more proof points of why we are confident around where we stand and how we see ourselves navigating into the future. Today, we will talk about forward-looking statements, and of course, those are subject to change as a disclaimer. It's important to, after three years, to take a little step back to where we have come from and essentially how we are preparing for the future. The first to say, growth was one of our fundamental pillars of our strategic reset. There we have clearly demonstrated, at least with Vyepti and Rexulti, that we have built a very compelling and durable growth curve, and we have essentially doubled the growth rate from what we said three years ago.

That's a fundamental important point as a proof point also of the ability of the organization to execute what it has and build a very strong and more durable growth engine. On the right-hand side, you see innovation, and this is an illustration really of what we had 2024, which was quite weighted towards lifecycle management and quite weighted also to early stage. We fundamentally, over the last three years, changed the profile of the company to five to six mid-to-late-stage assets that are really the answer to the long-term sustainable growth of the company. Also, transformation has really occurred in the innovation over the last three years in terms of our pipeline, and I'll talk more to that in a second.

But fundamentally, what we've also done, which is the middle part of this discussion, which is really strategic capital reallocation and being very clear on how we prepare the company for long-term sustainable growth. Here are elements really where we have constantly transformed our commercial model, one where we are serving different patients, smaller, rare populations, specialty populations. We have changed our commercial model also with regards to partnerships, where we are essentially ensuring that the partners on our behalf can reach a larger patient population than we can do.

And we have been able to also simplify a lot of our manufacturing. But at the same time, we are able to reinvest a lot of that into investing in future of the pipeline, but also investing into future areas, rare disease operating models and ways of how we prepare the company for the long-term sustainable growth.

So this is a fundamental part that I will talk more about, but these three pillars, we believe, have truly transformed Lundbeck from where we were three years ago. And this is setting us up for the next phase of our journey or the next chapter. So let me just dig in a little bit into the two areas that I want to highlight further. So Vyepti, it is, I would characterize as an outperform from three years ago.

We are able to continue to see, first of all, double-digit growth, high double digit, but also we are the fastest-growing anti-CGRP in this class, and that is not something we saw certainly three years ago. So again, very strong growth engine, one that we will continue to see advance into the midterm as an important growth contributor for the company.

On Rexulti, we are certainly seeing a space which is, of course, more competition, more crowded, but here again, we are delivering double-digit growth on a constant basis here with a clear focus on two indications, major depressive disorder and also Alzheimer's or agitation associated with Alzheimer's disease, where we are a first mover and an important growth engine for us as well. So just again, an illustration of durable growth, consistent execution, and a clear focus of the company around where we can play to win.

Now, I want to spend a bit more time on just giving you a few highlights of the pipeline, because this is truly transformative from what we've achieved three years ago. And this is the answer to the long-term growth of the company, is more shots on goal, more options than purely relying on one or two growth assets.

And again, I would just emphasize a few key comments to give you some additional color on the pipeline. The first is bexicaserin.

Of course, this was an acquisition of Longboard, but we have taken the asset through phase III and expect to have important pivotal readouts with the broader DEE label, which is called DEEp OCEAN study, at the end of this year, and then the DEEp SEA study in the first quarter of 2027, which will pave the way for us to seek a broader indication for this population, an area of high unmet need, especially in the space of a broad inclusion of DEE population that allows us to operate in this peak sales potential of DKK 1.5 billion-DKK 2 billion, which we will certainly see as we unfold the phase III results.

An important additional one is our amlenetug alpha-synuclein, where we have also completed randomization, and the study will, of course, read out in the third quarter of 2027 in a very severe population, high unmet need, no treatments today, multiple system atrophy, which is a devastating disease. Here, we are building on the strong proof of concept results now into phase III. So, two important near-term catalysts that are important for our long-term growth.

Beyond that, there's depth in the pipeline, and I think that's the message I want to leave you with. Depth in terms of further building on bocunebart, which is our anti-PACAP molecule in the chronic migraine space, where we have strong phase II-B data that now will lead us to phase III, still initiating that this year with first patient, first visit.

Also in the neurohormonal space, neuroendocrinology, we have a very strong proof of concept in asedebart, anti-ACTH, where we are seeing strong proof of concept data on normalization of cortisol with this asset, and an important future area of sort of adjacent growth for Lundbeck going forward. Then just to mention again here, additional ones, our D1/D2 agonists, showing very promising results in Parkinson's on time, which is a major area of unmet need, and we are very confident around this asset to advance it further into the future. When you look at this pipeline, it's one of depth and breadth with an important sense of quality of this pipeline. It's best-in-class or first-in-class assets that we see now advancing and are truly the proof points of building a long-term sustainable growth for Lundbeck.

On the pipeline itself, we can talk about numbers in different phases, but I think the most important thing I want to, which we haven't spoken about today, but just to signal for you, is certainly that our orexin program, which is a little earlier, is a very promising space, which we believe we will advance in further as well. Again, giving you just a sense of the breadth, the depth of the pipeline. My message here on pipeline is quality of pipeline. We have 16 special regulatory designations. It could either be breakthrough or orphan designation, and best-in-class, first-in-class molecules that allow us to build with great confidence where we see the long-term sustainable growth of the company.

The journey continues from here, and it's also about how we prepare ourselves for the next phase, which is really not a new strategy, but it's really a next chapter of where we are going, which is the scale phase.

We have built, in the last three years, a very strong, I would say, the muscles inside the company for capital reallocation, being very dynamic in our capital reallocation, ensuring in the last three years, we have been able to free up DKK 2.3 billion, which is roughly 10%-15% of our overall capital flexibility that we're creating, which is world-class. It allows us to dynamically invest based on pipeline or where we see further growth opportunities going forward. We are launching Vyepti in Asia, for example. That's an area of expansion for us going forward.

There is AI augmentation of the organization is another example of where we want to invest. Not going through all of these in detail, but I would say that we have prepared the company as a platform for further expansion and growth, and our ability to look at capital in a strategic way to fund that journey and to reach the full potential of the company is where the next phase will be. The scale phase is to expand really and build depth of the work that we have already done in the first three years of our multi-year strategy. Again, I think news that you would have received last week, but we have dynamically invested in our business, certainly in the first nine months of the year.

We have now, as we went through the first nine months, gained more certain visibility over elements like Vyepti, our ability to grow further in the commercial partner markets that gave us confidence around the upgrade of 11%-12%, and also further dynamics on our adjusted EBITDA with timing of R&D, but also seeing with additional sales, of course, additional gross profit. So there again, also guiding to double-digit adjusted EBITDA growth.

Lundbeck here is heading to another year where we are seeing double-digit growth and certainly much more than we expected three years ago. Again, fundamentals very strong also in the growth engine. Before we go to questions, I will leave you with, again, just a few highlights of what I have just spoken about, the proof points of where we are as a company and the confidence we have around where we are advancing.

We have delivered growth. We are seeing a more compelling pipeline going forward, and we have ensured that we could remain with a healthy profitability while investing for the long term and full potential of Lundbeck. That is also how we continue opening the next door, in a sense, to the strategy, the next chapter of the strategy, where we will build momentum on Vyepti, launching in Asia, of course, as we speak, and building also depth of our neuro rare potential in the pipeline for commercialization in the future. Of course, a strong pipeline, but we are not resting here.

We continue to look in our strategy in the phase of scaling where could we bolster the pipeline further, either with the organic work, but also inorganic opportunities to strengthen for the next wave of growth, where the clear focus of this strategy is what we are preparing in the next three years will allow us to have a decade of sustainable growth going forward from the end of 2029, 2030. Continuing to be strategic in our capital allocation to fully invest in the company because we believe, and what we see, it has very strong potential. With that, I believe we could go to some questions, Shan, if you would like.

Shan Hama
Analyst, Jefferies

Yes, of course. Firstly, are there any questions from the audience? No? I'll go ahead. Thank you very much for that, Charl. Maybe I'll start with Vyepti. This is a very, very important growth driver for Lundbeck. You recently said something along the lines of that a share point in the second line is worth around 4x the volume of a share point in fourth, fifth line.

How should we actually think about the magnitude of the Vyepti opportunity as Vyepti continues to move in early line treatment and the perceived IV headwind is not actually a headwind?

Charl van Zyl
CEO, Lundbeck

Yeah. Before I answer that, I want to also put a date on your calendar for December 8th, when we will have an event where we will talk more in depth about our migraine franchise and how we see the long-term potential. What I would say at this point is that we have built over the last three years a very strong business model around Vyepti, infusion network, education of patients, really building this ability to navigate through the friction points in healthcare for patients. We built a depth and experience with physicians, and we see through that there's a potential to move upstream. In other words, not cycling through many treatments, but going earlier to Vyepti. That is, of course, one of the key growth drivers for us in the future.

We're already seeing many of those examples where the earlier treatment cycle could have a better outcome than essentially cycling through a number of treatments. We will continue to focus on that as part of a expansion into newer patient populations. But we are also very focused on ensuring that we launch well in Asia, but we're also investing in Europe for building that depth of experience and efficacy that we see as a result of the IV. I think the biggest learning that we had over the last three years that we might have thought going into this was, would IV be a hurdle? We don't see that. We don't see that as a limitation to the expansion potential of Vyepti.

Shan Hama
Analyst, Jefferies

That is very clear.

Charl van Zyl
CEO, Lundbeck

Thank you.

Shan Hama
Analyst, Jefferies

If we think a little bit more broadly about the migraine treatment paradigm, of course, you also have bocunebart, which is your anti-PACAP. As you mentioned, first patient, first dose is pretty imminent. How do you envisage the migraine treatment paradigm evolving over the next couple of years, and how do you see bocunebart slotting into that treatment paradigm?

Charl van Zyl
CEO, Lundbeck

Yeah. Look, I think with anti-CGRPs, they really are transformational for patients, and we have seen the result of that also with Vyepti being the fastest-growing anti-CGRP. We also see patients that are not responding that well or are non-responders, so there is still an unmet need. With anti-PACAP, you are addressing another pathway and addressing a novel mechanism, and we are first in class there with an anti-PACAP, well ahead of competition. Our next phase is now [inaudible] in phase III. But we see the market potentially addressing these two mechanisms as a way of coexistence to treat unmet need, but also to potentially look at combinations in the future, because we think one mechanism will not be enough to fully satisfy the market.

Anti-PACAP is one that is entering into phase III now and can be an important additional mechanism to address the unmet need that still remains.

Shan Hama
Analyst, Jefferies

That is very clear. Thank you. Now perhaps let us move on to one of your nearest value drivers. You have the DEEp SEA and DEEp OCEAN.

Charl van Zyl
CEO, Lundbeck

Yeah.

Shan Hama
Analyst, Jefferies

Studies reading out very soon. How do you actually envisage building this broad DEE market? I mean, you have over 1,000 mutations in DEEs. Do you need physicians to identify specific genetic mutations, or is this a treatment that can be used more broadly without that genetic testing burden?

Charl van Zyl
CEO, Lundbeck

What we liked about the mechanism when we acquired Longboard was the potential for it to be much broader, and therefore also the studies we designed were there to include a representative population of the broader DEE space, so where we are more able to address excitatory or inhibitory responses with this broader mechanism of action. And that, of course, is what will come from the phase III.

If that is successful and we have confidence around the mechanism of action and what we saw in the phase II, that will give us the stepping stone towards a broader application in the market, of course. And I think what will be the benefit maybe for physicians will be able to go to bexicaserin as a broad treatment without having to classify or identify the subtype of DEE.

That is the ambition we are aiming for, to really shift that paradigm where there are today very few treatments for these broader populations of DEE.

Shan Hama
Analyst, Jefferies

That is very clear. Can I ask perhaps about the level of detail we could see in the release or releases? Is it enough for us to determine whether there is going to be that broad effect in DEEs?

Charl van Zyl
CEO, Lundbeck

Look, I think we will wait for the molecule and the patient to speak, but I think we are balancing often, just for all to understand, that sometimes the balance of amount of information through the headline results and also how we can secure long-term publications is one of the choices we need to make around how much we disclose. But we will do our best to inform the market as much as we can.

Shan Hama
Analyst, Jefferies

Understood. Thank you. Again, thinking a little bit more broadly, the epilepsy landscape is evolving pretty quickly. I mean, of course, you have Fintepla, which is pretty established, but you have a couple of other players coming online, both within DEEs, but then also DS specifically. How do you think about treatment sequencing in epilepsy going forward? How are physicians going to.

Charl van Zyl
CEO, Lundbeck

Yeah.

Shan Hama
Analyst, Jefferies

Pick the treatments for specific patients?

Charl van Zyl
CEO, Lundbeck

Look, I would only comment on what we know from current standard of care. Typically, these patients are severe, so there will be a number of treatments that will be tried as a standard of care. That is also how we designed the clinical program to what we would say is placebo is really actually standard of care of patients already on existing treatments. Then we would see the mechanism of bexicaserin being added on top of that with the seizure reduction potential that we would see from that.

So, we would aim with the clinical program to see broad efficacy that allows physicians to go with confidence to what they can see could have an effect across the population, including if they are on standard of care, adding on bexicaserin to that would be what we would aim for as a treatment paradigm.

Shan Hama
Analyst, Jefferies

Understood. Thank you. Perhaps if we move on to Rexulti. I believe you previously said that MDD growth should still be sustainable through 2027, 2028.

Charl van Zyl
CEO, Lundbeck

Yeah.

Shan Hama
Analyst, Jefferies

Alongside, of course, AADAD, which is the largest growth driver. Once you know the IRA negotiated price later this month, how should we think about that trade-off between the sort of continued volume growth and then the pricing impact before LOE?

Charl van Zyl
CEO, Lundbeck

Look, I think we will learn about the IRA pricing very much before the end of the year, and that will inform us a little bit how we model what the volume impact could be. But the impact is really in 2028, not in 2027. If I sort of come back to what is driving Rexulti right now, we have two indications, MDD, which is very competitive with other major players there, but we remain growing there in prescription level of nearly 14%. So the asset has a lot of brand recognition, a lot of reputation, and strength in the space. So we feel even with competition coming in, we have a very strong case there.

When you look at AADAD, which is an area where there hasn't been any new entrants, we have had the first mover advantage over the last three years, and there we are growing 29%. So we see that also as an area, even with new competition coming in, it remains a growth driver. So for us, as we get into the first quarter of next year, we will provide a bit more answer to your question around mid-term and how these effects might play into the mid-term. But what we see now is still a sustained growth of Vyepti going forward.

Shan Hama
Analyst, Jefferies

Very clear. At your 3Q earnings call, you specifically call out the 65+ segment.

Charl van Zyl
CEO, Lundbeck

Yeah.

Shan Hama
Analyst, Jefferies

I believe it is around 37% of the total Rexulti prescriptions. How much further can that mix go?

Charl van Zyl
CEO, Lundbeck

Yeah. Because today, we are seeing comorbidities in that population 65+ , and today that makes up 37% of our prescriptions. We see more to go there, more opportunity, and it is also an area where both our indications could play a role.

Shan Hama
Analyst, Jefferies

Very clear. Let's move on to amlenetug.

Charl van Zyl
CEO, Lundbeck

Mm-hmm. Yes.

Shan Hama
Analyst, Jefferies

Anti-alpha-synuclein for multiple system atrophy. This is another key catalyst for Lundbeck.

Charl van Zyl
CEO, Lundbeck

Yeah.

Shan Hama
Analyst, Jefferies

You have the phase III data 3Q 2027-ish, around that time. What would a compelling result look like for you beyond simply meeting the primary endpoint?

Charl van Zyl
CEO, Lundbeck

Yeah. Look, I think first of all, we are dealing with a patient population that has a rapid progression of the disease, seven, eight years from diagnosis to potentially death. So it's a very severe and fast-progressing disease, and it is in the clinical programs, it is measured through a functionality score, which is called UMSARS, or a modified UMSARS. So those are the well-recognized endpoints that we will learn from as we go into the headline results in Q3.

But if we achieve those, we know that that will have a meaningful clinical effect, and we believe that that's what we need to address. The ambition here is slowing down the progression to an extent where there's a longer quality of life and impact, of course, what that means to the individual patient.

Shan Hama
Analyst, Jefferies

Very clear. Have physicians sort of pointed to you or said what degree of slowing progression would be meaningful for them?

Charl van Zyl
CEO, Lundbeck

We saw in the proof of concept 27%, but that was in a small population. So we will now learn more. The study is powered to nearly 10-fold, 400 patients. So then we will see what that means, but that is already trending towards being significant in terms of primary endpoint.

Shan Hama
Analyst, Jefferies

Very clear. Then you have described 2027 as moving from this focus phase into the scale phase.

Charl van Zyl
CEO, Lundbeck

Yeah.

Shan Hama
Analyst, Jefferies

What changes for Lundbeck in this next phase? Where will we see the biggest investment, and what should investors expect to be materially different from now to the end of next year?

Charl van Zyl
CEO, Lundbeck

Yeah. Look, I think we see what we have today is a company that is well-poised for additional growth, but it is a company that we need to continue to invest in for reaching its full potential, meaning that we will remain higher than the peer group in our R&D investment, so 20%-25%. Might even exceed that, because we believe that is the long-term success of the strategy, and investing in that now will determine the long-term growth.

Then I would say we will come back certainly in Q1 with a better view of how we see growth based on different events that will come our way, based on some generic entrance, but also additional growth that we see from our strategic assets that will give you a sense of the corridor we will navigate through in the next few years.

But confident on where we stand right now with the platform we have.

Shan Hama
Analyst, Jefferies

That takes us to time. Thank you very much, Charl.

Charl van Zyl
CEO, Lundbeck

Thank you so much.